Abstracts tagged "Biologicals"

Abstract Number: 1352 • ACR Convergence 2020
Bimekizumab Maintenance of Response in Patients with Psoriatic Arthritis: 2-Year Results from a Phase 2b Dose-Ranging Study and Its Open-Label Extension
Joseph Merola¹, Frank Behrens², Alan Kivitz³, Philip Mease⁴, Iain McInnes⁵, Barbara Ink⁶, Deepak Assudani⁷, Paulatsya Joshi⁷, Jason Coarse⁸ and Christopher Ritchlin⁹, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ²CIRI/Rheumatology & Fraunhofer IME, Research Division Translational Medicine and Pharmacology, Goethe University Hospital, Frankfurt, Hessen, Germany, ³Altoona Center for Clinical Research/Altoona Arthritis and Osteoporosis Center, Duncansville, PA, ⁴Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ⁵Institute of Infection, Immunity, and Inflammation, University of Glasgow, Glasgow, United Kingdom, ⁶UCB Pharma, Slough, ⁷UCB Pharma, Slough, United Kingdom, ⁸UCB Pharma, Raleigh, NC, ⁹Department of Medicine, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Bimekizumab (BKZ), a humanized monoclonal IgG1 antibody that selectively neutralizes interleukin (IL)-17A and IL-17F, has shown clinical improvements in joint and skin outcomes over…
Abstract Number: 1536 • ACR Convergence 2020
Ultrasound as an Imaging Biomarker of Early Response to Tocilizumab and Methotrexate in Early Rheumatoid Arthritis, TOVERA – a Longitudinal Study
Maria S. Stoenoiu¹, Mihaela Maruseac², Mouna Messaoudi², Adrien Nzeusseu Toukap³ and Esperanza Naredo⁴, ¹1Department of Rheumatology, Cliniques Universitaires Saint-Luc, 2Institut de recherche expérimentale et cliniques (IREC), Brussels, Belgium, ²1Department of Rheumatology, Cliniques Universitaires Saint-Luc, Brussels, Belgium, ³1Department of Rheumatology, Cliniques Universitaires Saint Luc, 2Institut de recherche expérimentale et clinique (IREC), Brussels, Belgium, ⁴Department of Rheumatology, Joint and Bone Research Unit. Hospital Universitario Fundación Jiménez Díaz, IIS Fundación Jiménez Díaz and Universidad Autónoma de Madrid, Madrid, Spain
Background/Purpose: The combination of methotrexate (MTX) and tocilizumab (TCZ) has been proven to be superior to MTX alone in early rheumatoid arthritis (RA)1 and was…
Abstract Number: 1926 • ACR Convergence 2020
Efficacy of Adjunctive Methotrexate in Patients with Giant Cell Arteritis Treated with Tocilizumab Plus Prednisone Tapering: Subanalysis of a Phase 3 Trial
John H. Stone¹, Jian Han² and Shalini V. Mohan², ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Genentech, South San Francisco, CA
Background/Purpose: There is conflicting evidence for methotrexate (MTX) efficacy in giant cell arteritis (GCA).1,2 Subanalysis of data from the 52-week, double-blind, randomized controlled GiACTA trial…
Abstract Number: 0199 • ACR Convergence 2020
A Phase 1, Randomized, Open-label, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17, a Proposed, Higher Concentration Biosimilar (100 mg/mL) Adalimumab, in Healthy Subjects
Edward C Keystone¹, Daniel Furst*², Jonathan Kay³, EunJin Choi⁴, Antonia Davidson⁵, YunJu Bae⁴, Darin Brimhall⁶, SangJoon Lee⁴, SungHyun Kim⁴ and DaHye Kwak⁴, ¹Mount Sinai Hospital, Toronto, ON, Canada, ²Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ³University of Massachusetts Medical School, Worcester, MA, ⁴Celltrion, Inc., Incheon, Republic of Korea, ⁵PPD Development, Austin, TX, ⁶PPD Development, Las Vegas, NV
Background/Purpose: CT-P17 is a recombinant human monoclonal antibody that was developed as the first biosimilar adalimumab with high concentration (100 mg/mL) and citrate-free formulation. The…
Abstract Number: 0291 • ACR Convergence 2020
SLAMF7 and CD38 on NK Cells Represent Potential New Therapeutic Targets for Systemic Lupus Erythematosus
Morgane Humbel¹, Florence Bellanger², Craig Fenwick², Alice Horisberger², Camillo Ribi² and Denis Comte², ¹CHUV, Lausanne, Vaud, Switzerland, ²CHUV, Lausanne, Switzerland
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease characterized by the production of autoantibodies. For this reason, anti-B cell therapy seems to be…
Abstract Number: 0396 • ACR Convergence 2020
Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results from the Open-Label Period of a Phase 3 Trial
Dinesh Khanna¹, Celia J. F. Lin², Helen Spotswood³, Jeffrey Siegel², Daniel Furst*⁴ and Christopher Denton⁵, ¹University of Michigan, Ann Arbor, MI, ²Genentech, South San Francisco, CA, ³Roche Products Ltd, Welwyn Garden City, United Kingdom, ⁴Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ⁵University College London, London, United Kingdom
Background/Purpose: The anti–interleukin-6 (IL-6) receptor-α antibody tocilizumab (TCZ) demonstrated skin score improvement and forced vital capacity (FVC) preservation in patients with systemic sclerosis (SSc) in…
Abstract Number: 0601 • ACR Convergence 2020
The “Why” of Drug Discontinuation; Clinical Review of EMR Notes for 2,545 Patients with Rheumatic Diseases
Kent Kwas Huston¹, Simon Helfgott², Scott Milligan³, Jasvinder Singh⁴, Nehad Soloman⁵, Brandon Weil³ and Colin Edgerton⁶, ¹Kansas City Physician Partners, Kansas City, MO, ²BWH- HMS, Boston, MA, ³Trio Health, Louisville, CO, ⁴University of Alabama at Birmingham, Birmingham, AL, ⁵Arizona Arthritis & Rheumatology Associates, P.C., Peoria, AZ, ⁶Articularis Healthcare, Summerville, SC
Background/Purpose: Persistence on therapy is an important consideration in rheumatic diseases. There are multiple treatment options that influence long term disease management and a better…
Abstract Number: 0808 • ACR Convergence 2020
Time to Discontinuation of Tofacitinib and TNF Inhibitors in Rheumatoid Arthritis Patients with and Without Methotrexate: Real World Results from a Rheumatoid Arthritis Cohort
Mohammad Movahedi¹, Angela Cesta², Xiuying Li³, Edward C Keystone⁴ and Claire Bombardier⁵, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²Toronto General Hospital Research Institute, Toronto, ON, Canada, ³Toronto General Hospital Research Institute, Toronto, Canada, ⁴Mount Sinai Hospital, Toronto, ON, Canada, ⁵Institute for Work and Health, Toronto, ON, Canada
Background/Purpose: Tofacitinib (TOFA) is an oral, small molecule drug used for rheumatoid arthritis (RA) treatment and is prescribed alone or with methotrexate (MTX). TOFA can…
Abstract Number: 0883 • ACR Convergence 2020
Network Meta-Analysis of Long-Term Efficacy (ASAS40) of Biologic Disease-Modifying Anti-Rheumatic Drugs (bDMARDs) in bDMARD-Naïve Patients with Non-Radiographic Axial Spondyloarthritis
Sandeep Kiri¹, Mindy Kim², Marissa Betts³, Madhura Chitnis³, Kyle Fahrbach³, Jialu Tarpey³ and Monica Turner³, ¹UCB Pharma, Slough, England, United Kingdom, ²UCB Pharma, Smyrna, GA, ³Evidera, Waltham
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) have demonstrated large clinical improvements in patients with non-radiographic axial spondyloarthritis (nr-axSpA), with patients naïve to bDMARDs experiencing substantial…
Abstract Number: 1045 • ACR Convergence 2020
Biological therapy in atypical optic neuritis refractory to conventional treatment. A multicenter study with 19 patients.
Inigo Gonzalez-Mazon¹, Alba Herrero Morant², Lara Sanchez-Bilbao², David Martinez-Lopez³, Vanesa Calvo-Río⁴, Carmen Alvarez-Reguera², Santos Castañeda⁵, Esther Francisca Vicente-Rabaneda⁶, Rosalia Demetrio-Pablo², Ana Urruticoechea-Arana⁷, J. L. García-Serrano⁸, J. L. Callejas-Rubio⁸, Norberto Ortego⁸, José Luis Martín-Varillas⁹, Olga Maiz Alonso¹⁰, Ana Blanco¹¹, Francisco Javier Narváez¹², Susana Romero-Yuste¹³, Iñigo Rúa-Figueroa¹⁴, Paula Estrada¹⁵, Julio Sanchez¹⁶, Miguel Ángel González-Gay¹⁷ and Ricardo Blanco², ¹Hospital Universitario Marques de Valdecilla, Bezana, Spain, ²Hospital Universitario Marques de Valdecilla, Santander, Spain, ³Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁴H.U. Marques de Valdecilla, Santander, Spain, ⁵Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, ⁶Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, ⁷HOSPITAL CAN MISSES EIVISSA, Ibiza, Spain, ⁸Hospital Universitario San Cecilio, Granada, Spain, ⁹Hospital Sierrallana, Torrelavega, Spain, ¹⁰Hospital Universitario Donostia, San Sebastian, Pais Vasco, Spain, ¹¹Hospital Universitario Donostia, San Sebastian, Spain, ¹²Hospital Bellvitge, BARCELONA, Spain, ¹³H Pontevedra, Coruna, Spain, ¹⁴Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain, ¹⁵Hospital Universitario de Bellvitge, Barcelona, Spain, ¹⁶Hospital 12 Octubre, Madrid, Spain, ¹⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Optic Neuritis (ON) is an inflammation of the optic nerve. Its most common presentation is demyelinating typical ON. Atypical ON is rare, severe, non-demyelinating…
Abstract Number: 1353 • ACR Convergence 2020
Achievement of Remission Is Associated with Improvement in Functionality in Certolizumab Pegol-Treated Patients with Psoriatic Arthritis, Irrespective of Pre-Existing Radiographic Structural Damage
Laura Coates¹, Désirée van der Heijde², Lars Erik Kristensen³, William Tillett⁴, Jason Eells⁵, Tommi Nurminen⁶ and Atul Deodhar⁷, ¹University of Oxford, Oxford, United Kingdom, ²Leiden University Medical Center, Leiden, Netherlands, ³The Parker Institute Copenhagen Denmark, Copenhagen, Denmark, Bispebjerg and Frederiksberg, Denmark, ⁴Royal National Hospital for Rheumatic Diseases, Bath, UK; Department of Pharmacy and Pharmacology, University of Bath, Bath, UK, Bath, United Kingdom, ⁵UCB Pharma, Slough, United Kingdom, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷Oregon Health & Science University, Portland, OR
Background/Purpose: Pre-existing structural damage in patients with psoriatic arthritis (PsA) has been suggested to impact therapeutic improvements in disease activity and functional outcomes.1,2 Here we…
Abstract Number: 1575 • ACR Convergence 2020
CD6 Is a Target for Cancer Immunotherapy
Jeffrey Ruth¹, Mikel Gurrea Rubio², Kalana Athukorala³, Stephanie Rasmussen¹, Weber Daniel¹, Peggy Randon¹, M Asif Amin¹, Phillip Campbell¹, Pei-suen Tsou¹, Yang Mao-Draayer¹, Qi Wu⁴, Matthew Lind¹, Rosemary Gedert¹, Thomas Lanigan¹, Venkateshwar Keshamouni¹, Nora Singer⁵, Feng Lin⁶ and David Fox⁷, ¹University of Michigan, Ann Arbor, MI, ²Division of Rheumatology, University of Michigan, Canton, MI, ³University of Michigan, Ann Arbor, MN, ⁴University of Michigan, Ann Arbor, ⁵The MetroHealth System, Case Western Reserve University School of Medicine, Cleveland, OH, ⁶Cleveland Clinic Foundation, Cleveland, OH, ⁷Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Limitations of checkpoint inhibitor immunotherapy include induction of autoimmune syndromes and resistance of many cancers. Definition of additional molecular targets is required. CD6, expressed…
Abstract Number: 1991 • ACR Convergence 2020
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq², Mary Buckley³, Kathryn Torok⁴, Barbara Edelheit⁵, Kaleo Ede⁶, Christopher Liu⁷ and C. Egla Rabinovich⁸, ¹Hackensack University Medical Center, Hackensack, ²Montclair State University, Montclair, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Conneticut Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, AZ, ⁷U Pittsburgh, Pittsburgh, ⁸Duke University Hospital, Durham, NC
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
Abstract Number: 0204 • ACR Convergence 2020
Pharmacokinetics and Safety of CT-P17, a Proposed High Concentration (100 mg/mL) Adalimumab Biosimilar, in Comparison with EU-Approved Adalimumab and US-Licensed Adalimumab; Results of a Phase 1, Randomized, Double-blind, Three-arm, Single-dose Study in Healthy Subjects
KyungSang Yu¹, InJin Jang¹, HyeongSeok Lim², JangHee Hong³, MinGul Kim⁴, MinKyu Park⁵, Anhye Kim⁶, MinSoo Park⁷, JaeYong Chung⁸, JongLyul Ghim⁹, SeungHwan Lee¹, SeokKyu Yoon², InSun Kwon³, Daniel Furst*¹⁰, Edward C Keystone¹¹, SangJoon Lee¹², SungHyun Kim¹², YunJu Bae¹², JungBin Cha¹³, HyeJin Kang¹³ and Jonathan Kay¹⁴, ¹Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea, ²College of Medicine, University of Ulsan, Asan Medical Center, Seoul, Republic of Korea, ³Chungnam National University Hospital, Daejeon, Republic of Korea, ⁴College of Medicine, Jeonbuk National University, Jeonbuk, Republic of Korea, ⁵Chungbuk National University Hospital, Cheongju, Republic of Korea, ⁶CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea, ⁷Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea, ⁸Seoul National University Bundang Hospital, Seongnam, Republic of Korea, ⁹Inje University Busan Paik Hospital, Busan, Republic of Korea, ¹⁰Department of Medicine, Division of Rheumatology, University of California at Los Angeles, Los Angeles, California, USA, Los Angeles, CA, ¹¹Mount Sinai Hospital, Toronto, ON, Canada, ¹²Celltrion, Inc., Incheon, Republic of Korea, ¹³Celltion, Inc., Incheon, Republic of Korea, ¹⁴University of Massachusetts Medical School, Worcester, MA
Background/Purpose: CT-P17 was developed as the first biosimilar of the high concentration (100 mg/mL), citrate-free formulation of reference adalimumab. The purpose of this study was…
Abstract Number: 0347 • ACR Convergence 2020
In Two Phase-3 Trials, Guselkumab Reduced Fatigue over 52 Weeks in Patients with Psoriatic Arthritis and Demonstrated Independent Treatment Effects on Fatigue After Adjustment for Clinical Response (ACR20)
Proton Rahman¹, Philip Helliwell², Atul Deodhar³, Alexa Kollmeier⁴, Elizabeth Hsia⁵, Bei Zhou⁶, Xiwu Lin⁶, Chenglong Han⁶ and Philip Mease⁷, ¹Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Janssen Research & Development, LLC, La Jolla, CA, ⁵Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: DISCOVER 1 & 2 are phase-3 trials of guselkumab (GUS, an IL-23 inhibitor) in patients with psoriatic arthritis (PsA). In both trials, treatment with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].